title: Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
abstract: OBJECTIVE
  To investigate the effect of exenatide treatment on serum ghrelin levels in obese female patients with type 2 diabetes mellitus.
  
  
  METHODS
  Fourteen female patients with type 2 diabetes mellitus being treated with metformin and exenatide were enrolled. A mixed meal test was applied to the patients while continuing with their daily medications. Blood samples were taken before and at 60, 120, and 180 minutes following mixed meal test to measure serum total ghrelin, glucose, and insulin levels. The following week, exenatide treatment of the patients was paused for 24 hours and the same experimental procedures were repeated.
  
  
  RESULTS
  Serum ghrelin levels were suppressed significantly at 180 minutes with exenatide treatment compared with baseline (294.4 ± 57.5 versus 234.5 ± 59.4 pg/mL) (p < 0.001). Serum ghrelin levels at 180 minutes were statistically different when percentage change in serum ghrelin levels after mixed meal tests with and without exenatide usage were compared (p = 0.001). Estimated total area under the curve values for serum ghrelin concentrations was also significantly lower with exenatide compared with omitted treatment (p = 0.035).
  
  
  CONCLUSIONS
  These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide.
authors.affiliation: Bursa Yuksek Ihtisas Education and Research Hospital, Department of Internal Medicine, 16330 Bursa, Turkey.
authors.forename: Figen
authors.initials: F
authors.lastname: Topyildiz
authors.affiliation: Bursa Yuksek Ihtisas Education and Research Hospital, Department of Internal Medicine, 16330 Bursa, Turkey.
authors.forename: Sinem
authors.initials: S
authors.lastname: Kiyici
authors.affiliation: Uludag University Medical Faculty, Department of Pharmacology, 16059 Bursa, Turkey.
authors.forename: Zulfiye
authors.initials: Z
authors.lastname: Gul
authors.affiliation: Uludag University Medical Faculty, Department of Bio-Statistics, 16059 Bursa, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Sigirli
authors.affiliation: Bursa Yuksek Ihtisas Education and Research Hospital, Department of Endocrinology and Metabolism, 16330 Bursa, Turkey.
authors.forename: Metin
authors.initials: M
authors.lastname: Guclu
authors.affiliation: Bursa Yuksek Ihtisas Education and Research Hospital, Department of Endocrinology and Metabolism, 16330 Bursa, Turkey.
authors.forename: Gurcan
authors.initials: G
authors.lastname: Kisakol
authors.affiliation: Uludag University Medical Faculty, Department of Pharmacology, 16059 Bursa, Turkey.
authors.forename: Sinan
authors.initials: S
authors.lastname: Cavun
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy*; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D004435:Eating; D000077270:Exenatide; D005260:Female; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D010455:Peptides / Q000627:therapeutic use*; D019518:Postprandial Period; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D015415:Biomarkers; C515349:GHRL protein, human; D054439:Ghrelin; D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D014688:Venoms; D008687:Metformin; D000077270:Exenatide